Latest News, Press Releases & Events

HOPE-1 Clinical Trial for SPX-101 Is Enrolling CF Patients in Canada and Europe

CYSTIC FIBROSIS NEWS TODAY by Ana Belo Van Wijk, PhD – The first patient has been enrolled and dosed in the HOPE-1 Phase 2 clinical trial evaluating Spyryx Biosciences‘ investigational drug SPX-101 as a treatment for cystic fibrosis (CF). The HOPE-1 study (NCT03229252) will take place in Alberta and Ontario in Canada, the United Kingdom, France, and Portugal. […]

Continue Reading

Cystic Fibrosis News Today: Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing

In Interview, Spyryx CEO Talks of Potential of CF Treatment Now Entering Clinical Testing A preclinical study using animal models of cystic fibrosis (CF) showed that SPX-101, a treatment being developed by Spyryx Biosciences, effectively cleared lung mucus in the animals, regardless of the presence of genetic mutations that promote the development of the disease. […]

Continue Reading

Spyryx Biosciences Emerging Company Profile in BioCentury

EMERGING COMPANY PROFILE GOING SPLUNCING BY EMILY CUKIER-MEISNER, SENIOR WRITER Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than therapies targeting CFTR. CF is caused by defects in the […]

Continue Reading